This is a correction notice for: Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D DiNardo, Keith W Pratz, Kenichi Ishizawa, Toshihiro Miyamoto, Norio Komatsu, Yasuhiro Nakashima, Chikashi Yoshida, Noriko Fukuhara, Kensuke Usuki, Takahiro Yamauchi, Noboru Asada, Norio Asou, Ilseung Choi, Yasushi Miyazaki, Hideyuki Honda, Sumiko Okubo, Misaki Kurokawa, Ying Zhou, Jiuhong Zha, Jalaja Potluri, Itaru Matsumura, Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy, Japanese Journal of Clinical Oncology, Volume 52, Issue 1, January 2022, Pages 29–38, https://doi.org/10.1093/jjco/hyab170
In the originally published version of this manuscript, there was an error in Figure 2a.
Figure 2.
Rates of CR and CR+CRi (a), and investigator-assessed event-free survival (b). aStratified by age (18 to <75, ≥75 years) and cytogenetic risk (intermediate, poor). Aza, azacitidine; CI confidence interval; CR, complete response; CRi, CR with incomplete blood count recovery; HR, hazard ratio; Pbo, placebo; Ven, venetoclax.
The label: “Placebo-azacitidine (N = 3)” should read: “Placebo-azacitidine (N = 13)”.
The error and emendation are outlined only in this correction notice to preserve the published version of record.